Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763023 | 0.92 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4816565 | 0.87 | CNR1 (0.77) | CNR1 | |
| SCHEMBL4821944 | 0.85 | CNR1 (0.76) | CNR1 | |
| SCHEMBL4823830 | 0.85 | CNR1 (0.76) | CNR1 | |
| SCHEMBL4819820 | 0.84 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4818656 | 0.81 | CNR1 (0.71) | CNR1 | |
| SCHEMBL4819803 | 0.80 | CNR1 (0.81) | CNR1 | |
| SCHEMBL4822362 | 0.78 | CNR1 (0.75) | CNR1 | |
| SCHEMBL4823932 | 0.76 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4818819 | 0.76 | CNR1 (0.62) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2007039797-A1 | USE OF CANNABINOID RECEPTOR-1 ANTAGONIST FOR TREATING INFLAMMATION AND ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| US-7141669-B2 | Cannabiniod receptor ligands and uses thereof | PFIZER INC. (US) | 2006-11-28 | — | — | US | claimed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| EP-2321351-B1 | ANTIBODIES TO CCR2 | PFIZER (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9238691-B2 | Nucleic acids encoding antibodies to CCR2 | PFIZER INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | AMGEN FREMONT INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8710191-B2 | Antibodies to CCR2 | PFIZER INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1622902-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094417-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR1 13/4885 |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | CCR2, CCR1, CCR5 | CNR1 1110/4885 |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.